Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-03-12
2010-10-05
Gabel, Gailene R (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S002000, C435S007920, C435S372000, C435S373000, C435S287200, C435S973000, C436S501000, C436S540000, C436S010000, C436S056000, C436S063000, C436S811000
Reexamination Certificate
active
07807389
ABSTRACT:
Disclosed are compositions and methods related to joint inflammation diseases. Disclosed is the relationship between osteoclasts and inflammatory joint diseases and osteoclast precursor cells.
REFERENCES:
patent: 2004/0209316 (2004-10-01), Ritchlin et al.
Hirayama et al., Osteoclast formation and activity in the pathogenesis of osteoporosis in Rheumatoid Arthritis, Rheumatology 41: 1232-1239 (2002).
Jevon et al., Osteoclast formation from circulating precursors in Osteoporosis, Scand J Rheumatol 32: 95-100 (Jan. 1, 2003).
Li et al., Systemic TNFa Promotes Erosive Bone Resorption by Increasing the Number of CD11b+ Osteoclast Progenitors in the Periphery which are Dependent on RANK Signaling of Osteoclastogenesis, Journal of Bone and Mineral Research: JBMR Program and Abstracts (2002).
Gregoretti et al., Osteoclast precursors circulate n the peripheral blood of patients with aggressive multiple myeloma, Leukemia 9: 1392-1397 (1995).
Massey et al., Human Osteoclasts derive from CD14 positive monocytes, British Journal of Hematology 106: 167-170 (1999).
Aaronson and Horvath, 2002. A road map for those who don't know JAK-STAT.Science296:1653-55.
Abu-Amer et al.2000. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis [In Process Citation].J Biol Chem275(35):27307-10.
Anderson et al.A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.Nature1997; 390(6656):175-9.
Anolik et al. 2002. B lymphocyte depletion in the treatment of systemic lupus: phase I/II trial of rituximab in SLE.Arthritis Rheum47:S289.
Anolik et al.2003. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.Arthritis Rheum48:455-459.
Antoni, 2003. The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT).Arthritis&Rheumatism. 48: (9S):S265.
Arai et al.Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors.J Exp Med1999; 190(12):1741-54.
Arend and Dayer, 1990. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.Arthritis Rheum33:305-315.
Arend, 2001. The innate immune system in rheumatoid arthritis.Arthritis Rheum44:2224-34.
Arnett et al.1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.Arthritis Rheum.31:315-324.
Azuma et al.2000. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts.J Biol Chem275:4858-64.
Baechler et al.2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.Proc Natl Acad SciU S A 100:2610.
Bathon et al.2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.N Engl J Med343(22):1586-93.
Behar and Porcelli, 1995. Mechanisms of autoimmune disease induction. The role of the immune response to microbial pathogens.Arthritis Rheum38:458-476.
Bennett et al.2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.J Exp Med197:711-723.
Bertolini et al.1986. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.Nature319:516-518.
Blanco et al. 2001. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus.Science294:1540-1543.
Boyce et al.Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice.J Clin Invest1992; 90(4):1622-7.
Boyle et al.2003. Osteoclast differentiation and activation.Nature423:337-342.
Braun et al.2002. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.Lancet359:1187-1193.
Bromley and Woolley, 1984. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint.Arthritis Rheum.27:968-975.
Bromley et al.1985. Bidirectional erosion of cartilage in the rheumatoid knee joint.Ann Rheum Dis44:676.
Bywaters and Dixon, 1965. Paravertebral ossification in psoriatic arthritis.Annals of the Rheum. Dis.24:313-331.
Campbell et al.2001. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF.J Clin Invest107(12):1519-1527.
Cenci et al.2000. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha.J Clin Invest106(10):1229-37.
Chen and Goeddel, 2002. TNF-R1 signaling: a beautiful pathway.Science296:1634.
Childs et al.. 2001. Efficacy of Etanercept for Wear Debris-Induced Osteolysis.J. Bon. Min. Res.16:338-47.
Childs et al.2002. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis.J Bone Miner Res17:192-199.
Chomarat et al.2000. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages.Nat Immunol1:510-514.
Collin-Osdoby et al. 2001. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis.J Biol Chem276(23):20659-72.
Danning et al. 2000. Macrophage-derived cytokine and nuclear factor kappa B p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 43:1244-1256.
Daro et al. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand.J Immunol2000; 165(1):49-58.
De et al. 2003. Failure of monocytes of trauma patients to convert to immature dendritic cells is related to preferential macrophage-colony-stimulating factor-driven macrophage differentiation.J Immunol170:63556362.
Delneste et al. 2003. Interferon gamma switches monocyte differentiation from dendritic cells to macrophages.Blood101:143-150.
Demulder et al. 1993. Abnormalities in osteoclast precursors and marrow accessory cells in Paget's disease.Endocrinology133:1978-1982.
den Broeder et al. 2002. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.J Rheumatol29:2288-2298.
Dougall et al. 1999. RANK is essential for osteoclast and lymph node development.Genes Dev13(18):2412-24.
Douni et al. 1996. Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis.J. Inflam.47:27-38.
Drake et al. 1995. Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner.J Immunol154:2441-2447.
Esdaile et al. 1981. Deforming arthritis in systemic lupus erythematosus.Ann Rheum Dis40:124-126.
Faust et al. 1999. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. Journal of Cellular Biochemistry 72:67-80.
Fearon et al. 2003. Angiopoietins, growth factors, and vascular morphology in early arthritis.J Rheumatol30:260-268.
Feldmann et al. 1996. Rheumatoid arthritis.Cell85:307-310.
Flick et al. 2003. Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing.J Orthop Res21:676-683.
Franzoso et al. 1998. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture.J of Exp. Med.187(2):147-59.
Franzoso et al.1997. Requirement for NF-kappaB in osteoclast and B-cell development.Genes&Dev.11(24):3482-96.
Fujikawa et al.1996. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis.Ann.of Rheum.Dis.55:816-822.
Gladman et al.1995. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model.J Rheumatol22:675-679.
Gladman, 1998. Psoriatic arthritis. Rheumatic Diseases Clinics of North America 24:829-844.
Goldenberg and Cohen, 1978. Synovial membrane histopathology in the differential diagnosis of rhe
Haas-Smith Sally A.
Ritchlin Christopher T.
Schwarz Edward M.
Ballard Spahr LLP
Gabel Gailene R
University of Rochester
LandOfFree
Methods and compositions related to joint inflammation diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions related to joint inflammation diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions related to joint inflammation diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4193140